Vivian W. Pinn Symposium: Innovations in Autoimmune Disease Research and Care

Held on May 15, 2024, the 8th Annual Vivian W. Pinn Symposium brought together leading researchers and healthcare professionals to discuss the latest innovations in autoimmune disease research and care, emphasizing the importance of collaboration and interdisciplinary approaches. The event focused on autoimmune diseases, which disproportionately affect women, and explored how new discoveries are improving understanding, diagnosis, and treatment of these conditions.

Introduction and Welcome

Dr. Janine Austin Clayton, Director of the Office of Research on Women’s Health (ORWH), opened the symposium by underscoring NIH’s commitment to autoimmune disease research. She noted that NIH has funded over 1,400 grants related to autoimmune disease in recent years, and the newly established Office of Autoimmune Disease Research (OADR) aims to coordinate efforts across multiple institutes and centers. OADR also focuses on advancing research, fostering collaboration, and developing a central autoimmune disease research repository.

Keynote: Understanding the Immunome – Past, Present, and Future

Dr. Jane Buckner, President of the Benaroya Research Institute, discussed the immune system’s role in autoimmune diseases like type 1 diabetes (T1D), rheumatoid arthritis, and psoriasis. T cells, which normally protect the body from infections, mistakenly attack healthy tissues in autoimmune diseases. Dr. Buckner highlighted the role of genetic factors like PTPN2, which impairs regulatory T cells (Tregs) in individuals with T1D. While Treg-based therapies show promise, challenges remain in restoring balance to the immune system. Gene-editing technologies such as CRISPR are being explored to develop antigen-specific Tregs that could provide more targeted therapies for autoimmune diseases.

Genetics of Childhood-Onset Systemic Lupus Erythematosus (cSLE)

Dr. Laura Lewandowski highlighted childhood-onset systemic lupus erythematosus (cSLE), which affects about 20% of lupus patients but is far more severe than the adult-onset form. She discussed the need for more research into cSLE, especially in low-resource regions like sub-Saharan Africa and Southeast Asia, where lupus is more severe, leading to higher mortality rates. Genetic studies on cSLE have revealed a higher genetic load, and ongoing research aims to uncover both common and rare genetic variants that contribute to the disease. Dr. Lewandowski emphasized the importance of studying diverse populations to ensure a comprehensive understanding of lupus globally.

Anticytokine Autoantibodies

Dr. Steven Holland discussed a distinct syndrome prevalent among Southeast Asian immigrants, which involves the presence of anticytokine autoantibodies. These autoantibodies interfere with the immune system’s ability to combat infections like nontuberculous mycobacteria (NTM). His research suggests that exposure to the fungus Aspergillus may trigger autoimmune responses in genetically predisposed individuals. The syndrome primarily affects women and poses a severe risk of opportunistic infections. Advances in treatment, including therapies like rituximab that target B cells producing autoantibodies, have shown promise in managing the condition.

Genetic and Environmental Risk Factors of Autoimmune Diseases

Dr. Alison Motsinger-Reif presented findings from the Personalized Environment and Genes Study (PEGS), a large cohort study aimed at investigating the interplay between genetics, environmental exposures, and autoimmune diseases. PEGS has revealed strong associations between lifestyle factors like smoking and occupational exposures with autoimmune diseases. Dr. Motsinger-Reif highlighted the importance of studying environmental factors to understand disease triggers better and develop personalized healthcare interventions. The PEGS Explorer web tool was introduced to allow researchers to explore these complex associations further.

Fireside Chat: Turning Hope into Action – Empowering Communities to Advance Science

Dr. David Fajgenbaum shared his personal journey with idiopathic multicentric Castleman disease (iMCD), a rare autoimmune disorder. Dr. Fajgenbaum recounted his experience as a patient and how it drove him to co-found the Castleman Disease Collaborative Network (CDCN) to advance research on iMCD. His innovative approach includes repurposing FDA-approved drugs for rare diseases and using artificial intelligence to identify potential treatments. His efforts led to breakthroughs in iMCD treatment and contributed to 15 other potential treatment approaches. Dr. Fajgenbaum also co-founded Every Cure, a nonprofit organization aimed at finding new uses for existing drugs to treat diseases beyond their original purpose.

Inside Innovation: Intramural Impact at NIH

The symposium showcased groundbreaking research efforts within NIH, particularly those focused on the genetics of autoimmune diseases. These studies are crucial for understanding the genetic underpinnings of conditions like childhood-onset systemic lupus erythematosus and T1D. Genetic insights are helping researchers develop more targeted treatments for autoimmune diseases, while NIH initiatives like the Accelerating Medicines Partnership® (AMP® AIM) and the Team Science Leadership Scholars Program foster collaboration across institutes and disciplines.

Closing Capstone: Making a Difference

Dr. Gail Kerr, Professor of Medicine and Chief of Rheumatology at the Washington, D.C. Veterans Affairs Medical Center, discussed her work with veterans suffering from autoimmune diseases like rheumatoid arthritis. Dr. Kerr’s initiatives include the creation of the VA Rheumatoid Arthritis Registry, a national biorepository that collects data to improve patient care for veterans. She also emphasized the need for greater diversity in clinical trials and the medical workforce, highlighting the importance of addressing healthcare disparities among ethnic minorities.

Concluding Remarks

Dr. Vivian Pinn, the symposium’s namesake, delivered the closing remarks, celebrating the progress made in autoimmune disease research. She praised the establishment of the Office of Autoimmune Disease Research as a major step forward in addressing autoimmune conditions that disproportionately affect women. Dr. Pinn emphasized the importance of continued collaboration among researchers, clinicians, and advocacy groups to drive scientific breakthroughs that will improve outcomes for patients with autoimmune diseases.

The symposium concluded with a strong message of hope, underlining the critical role that synergy in science plays in advancing understanding, diagnosis, and treatment of autoimmune diseases, while ensuring that the unique health needs of women are addressed through dedicated research and collaborative efforts.